IDORSIA AG SF-,05
1,82€
-0,09 (-4,86%)
11.09.2024, 22:58:05 Uhr
WKN: A2DTEB ISIN: CH0363463438 Wertpapiertyp: Aktie Währung: Euro
- 1T
- 1W
- 1M
- 3M
- 6M
- 1J
- 3J
- 5J
- 10J
- Max
Weltmärkte
- DAX ® +175,11 +0,96% 18.505,38
- MDAX ® -93,27 -0,37% 25.105,73
- TecDAX ® +10,94 +0,34% 3.257,40
- E-STOXX 50 ® +16,38 +0,34% 4.763,58
- NASDAQ 100 +67,18 +0,35% 19.304,48
- HANG SENG +134,01 +0,78% 17.240,39
Kursperformance
| Zeitraum | Kurs | % |
|---|---|---|
| 1 Tag | 1,82€ | -4,86% |
| 1 Woche | 1,98€ | -8,13% |
| 1 Monat | 2,24€ | -18,82% |
| 6 Monate | 2,03€ | -10,52% |
| Lfd. Jahr (YTD) | 2,31€ | -21,11% |
| 1 Jahr | 4,21€ | -56,77% |
| 3 Jahre | 20,12€ | -90,96% |
| 5 Jahre | 23,56€ | -92,28% |
Kursdaten
| Kurs | 1,82€ |
| Eröffnung | 1,82€ |
| Geld | 0,00€ |
| Brief | 0,00€ |
| Tages-Hoch | 1,82€ |
| Tages-Tief | 1,82€ |
| 52 Wochen-Hoch | 4,49€ |
| 52 Wochen-Tief | 1,37€ |
| Allzeit-Hoch | 31,65€ |
| Allzeit-Tief | 1,37€ |
Nachrichten
- GlobeNewswire: New data with daridorexant to be presented at SLEEP 2024 - 03.06.2024, 07:00:00 Uhr
- GlobeNewswire: Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024 - 31.05.2024, 07:00:00 Uhr
- GlobeNewswire: Idorsia issues invitation to the 2024 Annual General Meeting of Shareholders - 23.05.2024, 07:00:00 Uhr
- GlobeNewswire: Idorsia announces changes to Idorsia Executive Committee and Board of Directors - 21.05.2024, 07:00:00 Uhr
- GlobeNewswire: Idorsia announces financial results for the first quarter 2024 – advancing the company with renewed vigor - 21.05.2024, 06:50:00 Uhr
- GlobeNewswire: Idorsia announces financial results for the full year of 2023 – Adapting the company to create sustainable value - 21.05.2024, 06:40:00 Uhr
- GlobeNewswire: Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call - 14.05.2024, 17:45:00 Uhr
- GlobeNewswire: Bondholders approve amended terms of the 2024 convertible bonds - 06.05.2024, 18:35:00 Uhr
- GlobeNewswire: Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond - 01.05.2024, 18:00:00 Uhr
- GlobeNewswire: JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension - 26.04.2024, 07:00:00 Uhr
